Arctoris To Overhaul Drug Discovery With Automation
Executive Summary
Building a robotics infrastructure "is the only way to make sure we generate data of sufficient quality at the speed and scale required, and now everybody in the pharma industry is very excited about the idea of end-to-end automation." So says Martin-Immanuel Bittner, CEO of Arctoris.
You may also be interested in...
Pheon Hopes To Stir Up ADC Space With First-In-Class Compound
The UK firm with a presence in Boston has just emerged but Pheon’s CEO Bertrand Damour tells Scrip that big pharma is already showing interest in its next-generation antibody-drug conjugate.
Lacutamab Data Boost Prospects For Innate Pharma
The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.
Leqvio Launch Will Be Fundamental To Success Of New Novartis
Discussion of the launch trajectory for the twice-yearly cholesterol therapy dominated the marketing portion of Novartis’s investor event and the firm is confident the foundations have been laid to push strong sales growth by the second half of next year.